(Q45903649)

17 December 2017

title

The effects of pergolide on memory and oxidative stress in a rat model of Parkinson's disease. (English)

1 reference

17 December 2017

author

Lucian Hritcu

4

1 reference

17 December 2017

author name string

Alin Ciobica

1

1 reference

17 December 2017

Zenovia Olteanu

2

1 reference

17 December 2017

Manuela Padurariu

3

1 reference

17 December 2017

publication date

18 October 2011

1 reference

17 December 2017

Journal of Physiology and Biochemistry

published in

1 reference

17 December 2017

volume

68

1 reference

17 December 2017

issue

1

1 reference

17 December 2017

page(s)

59-69

1 reference

17 December 2017

Parkinson's disease: Mitochondrial damage control

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Modeling operant behavior in the Parkinsonian rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Acute effects of 6-hydroxydopamine on dopaminergic neurons of the rat substantia nigra pars compacta in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide effect on cognitive functions in early-mild Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Effects of serotonin depletion on behavior and neuronal oxidative stress status in rat: relevance for anxiety and affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Spatial deficits in a mouse model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Iron as a cause of Parkinson disease - a myth or a well established hypothesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide protects dopaminergic neurons in primary culture under stress conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Cognitive effects of the dopamine receptor agonist pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

The effect of pergolide on cognitive performance of young and middle-aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Are dopamine receptor agonists neuroprotective in Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide interactions with nicotine and pilocarpine in rats on the radial-arm maze.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Dopaminergic enhancement of cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Alterations of Hrd1 expression in various encephalic regional neurons in 6-OHDA model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Behavioral dysfunction, brain oxidative stress, and impaired mitochondrial electron transfer in aging mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Effects of pergolide mesilate on metallothionein mRNAs expression in a mouse model for Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Effects of pergolide treatment on in vivo hydroxyl free radical formation during infusion of 6-hydroxydopamine in rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Spatial and object working memory deficits in Parkinson's disease are due to impairment in different underlying processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Dopamine agonists and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Molecular and clinical prodrome of Parkinson disease: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Spatial learning and memory deficits induced by dopamine administration with decreased glutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Pergolide protects SH-SY5Y cells against neurodegeneration induced by H(2)O(2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Iron and reactive oxygen species activity in parkinsonian substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Prenatal testosterone improves the spatial learning and memory by protein synthesis in different lobes of the brain in the male and female rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Effects of right-unilateral 6-hydroxydopamine infusion-induced memory impairment and oxidative stress: relevance for Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

Nicotine-induced memory impairment by increasing brain oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13105-011-0119-X

L-dopa increases nigral production of hydroxyl radicals in vivo: potential L-dopa toxicity?

21 January 2018

1 reference

12 December 2020

Psychomotor effects of dopamine infusion under decreased glutathione conditions

1 reference

12 December 2020

The effects of aging and oxidative stress on psychomotor and cognitive behavior

1 reference

12 December 2020

Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: implications for mitochondrial dysfunction in Parkinson disease

1 reference

12 December 2020

Murine model for Parkinson's disease: from 6-OH dopamine lesion to behavioral test

1 reference

12 December 2020

10.1007/S13105-011-0119-X

Identifiers

DOI

1 reference

17 December 2017

Dimensions Publication ID

1052191594

0 references

1 reference

17 December 2017